Effect of Sodium−Glucose Co-Transporter-2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-07-19 DOI:10.1002/clc.24303

Andreasová Taťána, Málek Filip

{"title":"Effect of Sodium−Glucose Co-Transporter-2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction","authors":"Andreasová Taťána, Málek Filip","doi":"10.1002/clc.24303","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The increased diuresis after sodium−glucose cotransporter 2 inhibitor (SGLT2i) was associated with a reduction of the estimated plasma volume (ePV) in type 2 diabetic patients.</p>\n </section>\n \n <section>\n \n <h3> Hypothesis</h3>\n \n <p>We hypothesized that the early effect of SGLT2i on ePV may be monitored by the change of biomarkers of hemoconcentration.</p>\n </section>\n \n <section>\n \n <h3> Patients and Methods</h3>\n \n <p>We analyzed the early- and long-term effect of SGLT2i empagliflozin on the ePV as assessed by biomarkers of hemoconcentration in a nondiabetic patient with heart failure and reduced ejection fraction (HFrEF) and a nondiabetic patient with heart failure and preserved ejection fraction (HFpEF). The ePV was calculated from hemoglobin and hematocrit levels by Duarte formula and ePV change was calculated by Strauss formula.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The ePV change was −22.56% between baseline and 1 month, and −37.60% between baseline and 12 months follow-up in a patient with HFrEF, and −6.18% and −16.40% in a patient with HFpEF, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The early effect of SGLT2i on ePV in patients with heart failure may be monitored by biomarkers of hemoconcentration.</p>\n </section>\n </div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clc.24303","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clc.24303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The increased diuresis after sodium−glucose cotransporter 2 inhibitor (SGLT2i) was associated with a reduction of the estimated plasma volume (ePV) in type 2 diabetic patients.

Hypothesis

We hypothesized that the early effect of SGLT2i on ePV may be monitored by the change of biomarkers of hemoconcentration.

Patients and Methods

We analyzed the early- and long-term effect of SGLT2i empagliflozin on the ePV as assessed by biomarkers of hemoconcentration in a nondiabetic patient with heart failure and reduced ejection fraction (HFrEF) and a nondiabetic patient with heart failure and preserved ejection fraction (HFpEF). The ePV was calculated from hemoglobin and hematocrit levels by Duarte formula and ePV change was calculated by Strauss formula.

Results

The ePV change was −22.56% between baseline and 1 month, and −37.60% between baseline and 12 months follow-up in a patient with HFrEF, and −6.18% and −16.40% in a patient with HFpEF, respectively.

Conclusion

The early effect of SGLT2i on ePV in patients with heart failure may be monitored by biomarkers of hemoconcentration.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

钠-葡萄糖共转运体-2 抑制剂对射血分数降低型心力衰竭患者和射血分数保留型心力衰竭患者估计血浆容量的影响

背景：钠-葡萄糖共转运体2抑制剂（SGLT2i）后的利尿增加与2型糖尿病患者估计血浆容量（ePV）的减少有关：我们假设 SGLT2i 对 ePV 的早期影响可通过血液浓缩生物标志物的变化来监测：我们分析了 SGLT2i Empagliflozin 对射血分数降低（HFrEF）的非糖尿病心力衰竭患者和射血分数保留（HFpEF）的非糖尿病心力衰竭患者的 ePV 的早期和长期影响，这些影响是通过血液浓缩的生物标志物评估的。通过杜阿尔特公式从血红蛋白和血细胞比容水平计算 ePV，并通过斯特劳斯公式计算 ePV 变化：结果：HFrEF 患者的 ePV 变化在基线至 1 个月期间为-22.56%，在基线至随访 12 个月期间为-37.60%；HFpEF 患者的 ePV 变化在基线至 12 个月期间分别为-6.18%和-16.40%：SGLT2i对心衰患者ePV的早期影响可通过血液浓缩的生物标志物来监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊